The Micro-Needle Revolution: How Tiny Silicon Spikes Are Going Global

NES ZIONA, Israel – November 26, 2025

A quiet revolution in medical injections is rapidly gaining global momentum. NanoPass Technologies, an Israeli pioneer in micro-electro-mechanical systems (MEMS), has announced a significant expansion of its commercial footprint, signing distribution agreements in Singapore, Mexico, Colombia, and Australia. This move propels the company's flagship product, the MicronJet™, into more than 30 countries and signals a strategic shift from deep-tech innovator to a global commercial force aiming to make its technology the new gold standard for intradermal delivery.

The expansion builds on a year of aggressive growth, with 28 new channels established across the United States, Canada, and major European markets. At the heart of this push is a device that replaces the century-old stainless-steel needle with a cluster of silicon-crystal pyramids, each shorter than a millimeter. The goal is to transform the patient experience and enhance clinical outcomes across fields as diverse as cosmetic dermatology and pandemic response.

Beyond the Pinch: The Science of Painless Precision

For many, the prospect of an injection evokes anxiety. The traditional hypodermic needle, while a medical workhorse, can be painful and cause bruising. Intradermal injections—which deliver substances into the skin layer rich with immune cells—are notoriously difficult to perform consistently with standard needles, a challenge known as the Mantoux technique. This inconsistency can lead to variable dosing and leakage, often discouraging practitioners from using this highly effective delivery route.

NanoPass's MicronJet™ platform was designed to solve these exact problems. Leveraging MEMS technology, the same fabrication process used to create microchips, the device features ultra-fine silicon-crystal pyramids that penetrate the skin to a precise, controlled depth. The design minimizes tissue trauma and avoids stimulating deeper nerve endings, resulting in a virtually painless experience. Independent research and patient feedback underscore this benefit, with over 80% of patients preferring it to standard needles and 95% grading the injection as painless or significantly less painful.

"It’s a game-changer for aesthetic practitioners," noted a leading dermatologist in an industry forum. "The ability to deliver product at a controlled depth of 600 or 800 micrometers allows for comfortable procedures with a very low risk of bruising, even in delicate areas around the eyes." The company offers two models to address specific needs: the MicronJet™ 600 (0.6 mm) for skin rejuvenation, local anesthesia, and treating hyperhidrosis, and the newly launched MicronJet™ 800 (0.8 mm), optimized for more viscous formulations used in procedures like hair restoration.

From Lab Bench to Global Marketplace

The journey from a promising technology to a globally adopted product is fraught with regulatory and clinical hurdles. NanoPass's current commercial acceleration is built on a solid foundation of extensive validation. The MicronJet™ is supported by over 70 completed and ongoing clinical studies involving more than 7,500 patients, from infants to the elderly. This exhaustive research forms one of the industry's most comprehensive databases on intradermal delivery.

Crucially, the device has secured regulatory clearance in major markets, including 510(k) clearance from the U.S. FDA, the EU's CE mark, and approvals from health authorities in China, Brazil, South Korea, and Australia. This web of approvals is the passport enabling the company's rapid global rollout and its strategic pivot.

"This expansion marks another milestone in NanoPass's transformation from a deep-tech innovator into a truly global commercial organization," said Daniel Levitats, CEO of NanoPass Technologies. "Our goal is to make MicronJet™ the universal gold standard for intradermal delivery across aesthetics, vaccines, and advanced therapeutics by combining MEMS technology precision with unmatched patient comfort."

This shift is not merely about selling a device; it's about creating a new standard of care. By providing a reliable, easy-to-use tool, NanoPass is making the benefits of intradermal delivery accessible to a much broader range of clinicians who previously shied away from the difficult traditional technique.

The Ripple Effect: Aesthetics, Vaccines, and Beyond

While the booming medical aesthetics market is the primary engine for near-term commercial growth, the long-term vision for MicronJet™ extends into far more critical areas of public health. The technology's most profound impact may lie in its application for vaccines and immunotherapies.

Intradermal delivery targets the skin's dense network of antigen-presenting cells, which can trigger a more robust and efficient immune response than deeper intramuscular injections. Clinical studies have shown that MicronJet™ can achieve a superior immune response with a fraction of the standard vaccine dose. This "dose-sparing" capability is a monumental advantage. For expensive biologics or during a pandemic when vaccine supplies are limited, the ability to vaccinate three to five times more people with the same amount of antigen could save millions of lives and dramatically reduce costs.

NanoPass is already collaborating with leading pharmaceutical and biotech firms on this front. Emergex, for example, initiated a Phase I clinical study for its T-cell adaptive COVID-19 vaccine using the MicronJet™. The platform is also being explored for immunotherapies targeting cancer, allergies, and Type 1 diabetes.

"We witness tremendous momentum from both partners and clinicians worldwide," added Tal Shlezinger, VP of Sales & Marketing. "MicronJet™ brings physicians a proven, evidence-backed solution that enhances both clinical results and the patient experience."

This dual strategy—leveraging high-margin aesthetic applications to fund and fuel expansion into the massive vaccine and therapeutic markets—positions NanoPass to disrupt multiple sectors simultaneously. It’s a calculated approach that turns cosmetic clinics into proving grounds for a technology poised to tackle global health challenges. The small, painless injections being used today for skin rejuvenation are paving the way for a future where vaccinations are more effective, less costly, and accessible to more people around the world.